CliffBio
small molecule

INBRIJA

LEVODOPA

Loss of exclusivityOctober 2033latest FDA-listed patent expiry
CompanyMerz Pharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameINBRIJA
Active ingredientLEVODOPA
Strength42MG
Dosage formPOWDER
RouteINHALATION
ModalitySmall molecule
FDA approvalDecember 2018
Marketing statusRX

Listed patents

PatentExpiresType
12458615October 2033use U-2484
8685442November 2032product
8945612November 2032product
8545878November 2032product
9393210November 2032product
RE43711February 2029use U-2484

More from Merz Pharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

INBRIJA patent cliff — loss of exclusivity October 2033 | CliffBio